clinical trial · NCT06821542
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
Chronic Graft-versus-host-diseaseINCA034176Best Available Therapy (BAT)
brief summary
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
started
Jun 4, 2025
primary completion
May 31, 2028
completion
Nov 30, 2032
last updated
Mar 23, 2026
official title
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol